Anika Therapeutics (ANIK) Liabilities from Discontinued Operations (2023 - 2024)
Anika Therapeutics (ANIK) reported Liabilities from Discontinued Operations of 659000.0 for Q4 2024, down 33.37% year-over-year from 989000.0 in Q1 2024, and down 33.37% quarter-over-quarter from 989000.0 in Q4 2023.
Anika Therapeutics (ANIK) Liabilities from Discontinued Operations (2023 - 2024) Analysis & Trends
Anika Therapeutics (ANIK) has 2 years of Liabilities from Discontinued Operations data on file, last reported at 659000.0 in Q4 2024.
- Liabilities from Discontinued Operations for Q4 2024 came in at 659000.0, down 33.37% year-over-year; the trailing twelve-month figure through Dec 2024 was 659000.0 (down 33.37% YoY), and the FY2024 annual result was 659000.0, down 33.37% from the prior year.
- Liabilities from Discontinued Operations declined to 659000.0 in Q4 2024 per ANIK's latest filing, from 989000.0 in the prior quarter.
- Over five years, Liabilities from Discontinued Operations peaked at 989000.0 in Q4 2023 and troughed at 659000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Anika Therapeutics | 197.89 Mn | 131.10 Mn | 19.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 659,000.00 |
| Dec 31, 2024 | 659,000.00 |
| Dec 31, 2023 | 989,000.00 |
| Dec 31, 2023 | 989,000.00 |